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Abstract
Background: How smokeless tobacco contributes to non-neoplastic oral diseases is unclear. It certainly
increases risk of oral mucosal lesions, but reviewers disagree as to other conditions. In some areas,
especially South-East Asia, risk is difficult to quantify due to the many products, compositions (including
non-tobacco ingredients), and usage practices involved. This review considers studies from Europe (in
practice mainly Scandinavia) and from the USA.
Methods: Experimental and epidemiological studies published in 1963–2007 were identified that related
risk of oral lesions to smokeless tobacco use. Data were assessed separately for oral mucosal lesions,
periodontal and gingival diseases, dental caries and tooth loss, and oral pain.
Results: Oral mucosal lesions: Thirty-three epidemiological studies consistently show a strong dose-related
effect of current snuff on oral mucosal lesion prevalence. In Scandinavia, users have a near 100% prevalence
of a characteristic "snuff-induced lesion", but prevalence of the varied lesions reported in the USA is lower.
Associations with chewing tobacco are weaker. The lack of clear association with former use suggests
reversibility following cessation, consistent with experimental studies showing rapid lesion regression on
quitting.
Periodontal and gingival diseases: Two of four studies report a significant association of snuff with attachment
loss and four out of eight with gingival recession. Snuff is not clearly related to gingivitis or periodontal
diseases. Limited evidence suggests chewing tobacco is unrelated to periodontal or gingival diseases.
Tooth loss: Swedish studies show no association with snuff, but one US study reported an association with
snuff, and another with chewing tobacco.
Dental caries: Evidence from nine studies suggests a possible relationship with use of smokeless tobacco,
particularly chewing tobacco, and the risk of dental caries.
Oral pain: Limited evidence precludes any clear conclusion.
Conclusion:  This review confirms the strong association of current use of smokeless tobacco,
particularly snuff, with prevalence of oral mucosal lesions. It provides suggestive evidence of an association
of snuff use with gingival recession and attachment loss, and of chewing tobacco with dental caries. While
smokeless tobacco clearly increases risk of oral mucosal lesions, interpretation for other endpoints is
limited by study weaknesses, including poor confounding control.
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Background
This review concerns epidemiological studies that relate
smokeless tobacco [ST] use to non-neoplastic oral dis-
eases and is based primarily on 50 publications, 20 in
Scandinavia [1-20], 29 in the USA [21-49] and one in Eng-
land [50]. In these countries, usage is mainly oral; nasal
use of finely ground "dry snuff" has become rare [51]. ST
products are traditionally classified as snuff or chewing
tobacco (CT) [52]. In the USA, CT is typically mixed with
saliva and then placed in the buccal pouch, while finely
cut "moist snuff" is frequently held in the lower labial
fold. In Scandinavia, snuff (or snus in Sweden) is gener-
ally placed under the upper or lower lip. As in some other
reviews of ST effects [53-57] results from areas (such as
India, South Asia, Africa and Saudi Arabia) where the
tobacco chewed is often mixed with other substances,
such as betel quid and areca nut are not considered [58].
Nor is oral cancer considered, as its relationship with ST
has been discussed elsewhere [57].
An earlier review of non-cancerous and precancerous oral
health effects associated with ST use was published by the
US Surgeon General in 1986 [53]. This report concluded
that "smokeless tobacco is responsible for the develop-
ment of a portion of oral leukoplakias in both teenage
and adult users" and that "dose response effects have been
noted by a number of investigators". However, it also
noted that "studies of the effects of smokeless tobacco use
on gingival and periodontal tissues have resulted in equiv-
ocal findings" and that "negative health effects on the
teeth from smokeless tobacco use are suspected but
unconfirmed". Since that time there have been many
reviews of the evidence relating ST use to oral changes
[54,55,59-71].
While these reviews are consistent in concluding that ST
use is associated with an increased risk of oral mucosal
lesions, they are far less consistent with regard to other
endpoints. Though various reviews [54,60,61,67] com-
ment on a possible relationship with gingival recession,
they disagree on whether an association is clearly demon-
strated or not. Similarly, views vary over whether associa-
tions with periodontal diseases and dental caries have not
been demonstrated [60], are possibly related, based on
limited evidence [69], or have been shown to exist
[54,67]. A number of these reviews [63,64,68,70,71] note
that "ST-related" oral mucosal lesions reverse on quitting
and go on to discuss the extent to which the presence of
the lesion modifies the risk of oral cancer. A recent review
by the US Surgeon General [72] notes that leukoplakia is
a classic precursor lesion of oral cancer, but notes that "the
leukoplakia that occurs in cigarette smokers differs mor-
phologically from the keratoses caused by smokeless
tobacco; although less common, the leukoplakia induced
by cigarettes is more susceptible to malignant transforma-
tions," citing a review by Bouquot [73]. The importance of
distinguishing the oral mucosal lesions induced by ST
from oral leukoplakias has also been emphasised by other
reviewers [74,75].
Our objective, therefore, was to try to clarify the overall
picture by conducting a detailed review of the available
evidence.
Methods
Study identification and selection
Results were identified from a systematic search of
MEDLINE, EMBASE, and SCOPUS through November
2007. The search was not limited by period or language.
The main searches were based on combinations of the
terms "smokeless tobacco", "chewing tobacco" and
"snuff" for exposure, and "oral diseases", "mouth dis-
eases", "periodontal diseases", "leukoplakia", "mucosal
lesions", "gingivitis", "gingival recession", "teeth prob-
lems", and "dental caries" for outcome. Further articles
were identified by inspection of reference lists in individ-
ual papers and reviews.
All reports had to satisfy the following Inclusion criteria:
published in a peer reviewed journal or publicly available;
based on research in humans; of experimental, cohort,
case-control design or cross-sectional design; study loca-
tion specified; conducted in North America or Europe;
non-neoplastic form of oral disease (ICD 9 520–529) as
the outcome; and CT, orally used moist snuff, or unspeci-
fied ST as the exposure. They also had to satisfy the Exclu-
sion criteria: oral cancer, sample included in a more
complete or recent study; inappropriate design (case
report, qualitative study or review); and appropriate prev-
alence estimates or odds ratios (ORs) not reported and
cannot be computed from the available data.
Data extraction
From each report, details were abstracted relating to the
study (design, period, region, population, sample selec-
tion, and size), the exposure (method of assessment, type
of ST investigated, exposure doses and durations consid-
ered), the outcome (type of oral disease and method of
diagnosis), and issues relating to analysis (type of effect
measure, analysis methods, stratification variables, and
adjustment factors).
Data were considered separately under four disease
groups: oral mucosal lesions, periodontal and gingival
diseases, dental caries and tooth loss, and oral pain. Addi-
tionally, a summary description of each study was pre-
pared, sorted by study design.
In some studies, the required estimates of prevalence, or
of effect size and precision, were not given by the authorsBMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
Page 3 of 20
(page number not for citation purposes)
and had to be estimated from data presented. Crude ORs
and 95% confidence intervals (CIs) were derived from the
relevant 2 × 2 table using standard methods, with, where
necessary, numbers estimated from proportions given
numerically.
Results
50 principal studies were identified, 20 of snuff, con-
ducted in Scandinavia (two in Denmark, one in Finland
and 17 in Sweden), 29 of CT, snuff or overall ST, con-
ducted in the USA, and one of CT, conducted in England.
No relevant studies were identified from other parts of
North America or Europe. Table 1 (Europe) and Table 2
(USA) give some details of the 50 studies considered. Both
tables are sorted by type of study and then by year of pub-
lication within type. Six are experimental studies investi-
gating the short-term effect on oral mucosal lesions of
quitting ST use, switching to a different brand of snuff, or
changing the site of placement of the snuff. Of the 44 epi-
demiological studies, three are prospective studies and
two are case-control studies, though one [5] is a case-con-
trol study of oral and oropharyngeal cancer, with only the
control group providing data relevant to this report. There
are 39 cross-sectional studies, 26 of populations unse-
lected by ST use and 13 of populations selected by ST use
and/or presence of oral lesions. Some of the 50 studies are
not independent. Thus, two studies [1,19] involve a sub-
set of subjects selected from those in a third [18], while
one study [38] gives combined results from a number of
groups of baseball players, the results for two of these
being previously reported [31,34]. Also, three studies
[40,42,43] give results for different endpoints using differ-
ently selected samples from the third National Health and
Nutrition Examination Survey (NHANES III).
The earliest publication [13] was in 1963, with five studies
published in the 1970s, 13 in the 1980s, 18 in the 1990s
and 13 since 2000. Many of the studies did not give details
on when they were conducted. Of the 50 studies, 24 were
of males and females, and 24 of males. Two studies [2,3]
did not give details on the sex of their subjects. Most of the
studies were mainly or wholly of adults, but there were 10
cross-sectional studies of children, mainly of school stu-
dents, but including one of adolescent football players
aged 11 to 18 [32] and one of teenagers attending dental
health check-up [9]. Some of the studies of adults
involved quite young populations, including air force
trainees [23], military recruits [7], college athletes [46], 19
year olds [12] and baseball players [31,34-36,38,44]. Oral
mucosal lesions were considered in 40 of the studies, with
19 considering indices of periodontal or gingival diseases,
10 dental caries, and three oral pain.
Oral mucosal lesions
Fifteen of the studies in Scandinavia provided informa-
tion relating ST use to oral mucosal lesions. As shown in
Table 3, 11 of these used the endpoint "snuff-dipper's
lesion" as defined by Axéll et al [15] and a further three
used an endpoint which appeared to be similar. For con-
venience we will refer to these 14 studies as being of snuff-
induced lesions (SIL). Only in one study [14] was a clearly
different endpoint used, of "oral leukoplakia", which
could occur both in users and non-users of snuff.
Table 4 summarizes the main results from the Scandina-
vian studies relating oral mucosal lesions to the use of
moist snuff (snus). The single study of oral leukoplakia
[14], in Denmark, had no control group so could not
compare lesion prevalence in snuff users and non-users,
though it reported that only 32 of the 450 oral leukopla-
kia cases studied used snuff and that the presence of symp-
toms (such as pain or rough feel to the tongue) was much
less prevalent in those who used snuff (3.1%) than in
those who did not (23.1%, p < 0.01).
The remaining 14 studies generally reported a 100% prev-
alence of SIL in snuff users. Partly this was because in
seven studies [1,3,4,13,15-17] subjects had been, or
appeared to have been, selected on the basis of SIL being
present, but this was not always the case [2,5,18,19]. The
only exceptions were a study in Finland [7] in which all
the users with no lesion had either quit or started snuff in
the previous three weeks, and a recent study of ice-hockey
players in Sweden [20] which reported no lesions in five
users of portion-bag snuff. One study in Sweden [8]
reported total numbers of lesions, but prevalence seems
likely to have been very high in snuff users.
As is evident from the results of the cross-sectional and
case-control studies summarized in Table 4, severity of SIL
was clearly associated with the length of time per day
snuff was used for and with the amount of snuff con-
sumed per day [5,15,16,18,20], though the statistical sig-
nificance of these relationships could not always be
determined. The relationship of severity with duration of
use was less marked [5,16,18]. Severity was also lower in
users of portion-bag snuff than in users of loose snuff
[19,20].
A number of the experimental and epidemiological stud-
ies investigated the effect of changing snuff habits on the
presence and severity of SIL. The data in Table 4 are all
consistent with quitting in the short-term reducing the
severity of the lesion [17] and in the longer term eliminat-
ing the lesion [1,4,7], and switching to lower nicotine,
lower pH or portion-bag snuff also reducing severity [1-4].BMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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Table 1: Details of European studies considered.
First author, year of 
publication
Location Study 
Perioda
Sex Age Population Further details of 
study design
Endpointsb
Experimental studies
Larsson 1991 [1] Sweden 
(Malmö)
3 to 6 months M 21 to 70 
Mean 36
29 snuff users with 
degree 2 to 4 
mucosal lesions 
selected from 
Andersson 1989 
[18]
Subjects advised to 
stop or change their 
habit
ML
Andersson 1995 [2] Sweden 
(Malmö)
12 weeks Not 
given
Mean 37 24 users of snuff 
brand A, 18 users 
of low-nicotine 
snuff brand B
Subjects observed for 
2 weeks, then brand A 
users switched to 
brand B for 10 weeksc
ML
Andersson 2003 [3] Sweden 
(Malmö)
24 weeks Not 
given
Mean 34 20 users of snuff 
brand A with 
degree 3 or 4 
lesions
Subjects switched to 
brand B with lower 
pH for 12 weeks, then 
to brand C with same 
pH as brand B but 
lower nicotined
ML
Prospective studies
Roosaar 2006 [4] Sweden 
(Uppsala 
county)
1973–1974 to 
2002
M 15+ 1115 men with 
"snus-induced 
lesions" in 
1973–1974 
followed up
Selected from 7890 
men examined
ML
Case-control studies
Rosenquist 2005 [5] Sweden 
(South)
2001 to 2004 M+F 33 to 87 132 cases of oral 
and oropharyngeal 
squamous cell 
carcinomas, 320 
population controls
Cases and controls 
matched on age ± 3 
years, sex and county
ML
Cross-sectional studies of populations unselected by ST use
Tyldesley 1971 [50] England 
(Lancashire)
Not given M Not given 402 coal miners - ML
Modéer 1980 [6] Sweden 
(Stockholm)
Not given M+F 13 to 14 
Mean 13.5
232 school children - PD
Jungell 1985 [7] Finland 
(Tammisaari)
Not given M 17 to 29 441 military 
recruits
-M L
Salonen 1990 [8] Sweden 
(Älvsborg 
county)
1983 To 1984 Me 20+ 477 randomly 
selected male 
adults
-M L
Hirsch 1991 [9] Sweden 
(Gothenburg)
Not given M+F 14 to 19 
Mean 16.8
2145 teenagers 
attending for dental 
check-up
-D C
Wickholm 2004 [10] Sweden 
(National)
1985 M+F 31 to 40 1674 adults born 
on 20th of month
-P D
Bergström 2006 [11] Sweden 
(National)
2002 to 2003 M 26 to 54 84 submariners - PD, DC
Montén 2006 [12] Sweden 
(Göteborg)
Not given M 19 103 never smokers Subsample from larger 
epidemiological study
PDBMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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While it is clear from the above that SIL occurs in virtually
all current users of moist snuff, with severity related to
extent of use, the data in Table 4 tell us little about the
long-term health implications of the lesion. The study by
Roosaar et al [4] provides some additional information.
Here 1,115 individuals with SIL were followed-up for 27–
29 years, with a total of three incident cases of oral cancer
seen, two in concomitant daily smokers. Though this was
somewhat higher than expected (standardized incidence
rate 2.3, 95% CI 0.5–6.7), none of the three occurred at
the site of the original SIL.
Of the 15 Scandinavian studies considered, 14 consider
use of moist snuff only and not other types of ST. The
study of Andersson et al [19], however, considered nine
users of CT as well as 45 snuff users. They noted that seven
of the CT users showed leukoedema in the buccal mucosa,
and that six who placed the tobacco on a permanent site
had degree 1 or 2 (Axéll) lesions at the site of placement.
The single study in England [50], of coal miners, reported
that 10 out of 280 CT users, 3.6%, had leukoplakia, as
compared to none out of 122 non-chewers (p = 0.05).
Here leukoplakia was defined as "a white patch that could
not be rubbed off and which could not be diagnosed as
being due to any other disease".
Twenty-four US studies provided evidence relating ST use
to oral mucosal lesions. As shown in Table 5, the defini-
tions of the endpoint used varied widely. Eight studies
[22,27,28,30,33,36,44,48] used a definition modified by
Greer and Poulson [27] from that used by Axéll [15], and
at least three studies [34,35,38,39] used a similar defini-
tion. However, in some studies the endpoints were clearly
not comparable, including one [42] where the endpoint
was any type of oral lesion and one [47] where the defini-
tion specifically excluded alterations that resolved rapidly
on discontinuation of ST use. Unlike the studies in Scan-
dinavia, the conditions were usually referred to as oral
leukoplakia or as oral lesions, with no specific reference to
ST or snuff in the name of the condition, as in SIL. An
exception was the Tomar et al study [39] which referred to
the endpoint as "smokeless tobacco lesions". Indeed it is
clear from Table 6, which presents the prevalence of these
lesions in relation to ST use, that the endpoint definitions
did not exclude the possibility of the lesion being present
in non-users of ST. In fact, in all but one of the 15 studies
which presented findings separately for users and non-
users, including the Tomar et al study, prevalence is
greater than zero in the non-users.
Exposure is classified in Table 6 by type (ST, snuff or CT)
and by time (current, former, ever or unspecified use
Cross-sectional studies of populations selected by ST use and/or presence of oral lesions
Pindborg 1963 [13] Denmark 
(Copenhagen)
Not given M 39 to 83 12 long-term snuff 
users
SIL probable inclusion 
criterion
ML
Roed-Petersen 1973 [14] Denmark 
(Copenhagen)
1956 to 1970 M+F < 20 to 90+ 
Mean 55
450 oral 
leukoplakia patients
-M L ,  O P
Axéll 1976 [15] Sweden 
(Not given)
Not given M 20 to 88 
Mean 50
114 snuff users 
with oral lesions
-M L
Hirsch 1982 [16] Sweden 
(Gothenburg)
Not given M 15 to 84 
Mean 41
50 habitual snuff 
users
SIL probable inclusion 
criterion
ML
Frithiof 1983 [17] Sweden 
(Stockholm)
Not given M 31 to 79 
Mean 55
21 long-term snuff 
users referred to 
dental school for 
oral lesions
-M L ,  P D
Andersson 1989 [18] Sweden 
(Malmö)
1986 to 1987 M 17 to 80 
Mean 36
252 snuff users; 
construction and 
shipyard workers 
and outpatients
-M L ,  P D
Andersson 1994 [19] Sweden 
(Malmö)
Not given M 21 to 75 
Mean 42
45 habitual snuff 
users and 9 users of 
CT selected from 
Andersson 1989 
[18]
Loose and portion-bag 
users matched on 
consumption and 
usage
ML
Rolandsson 2005 [20] Sweden 
(Värmland)
Not given M 16 to 25 
Mean 21
80 ice hockey 
players, of which 40 
were snuff users 
and 40 non users
Snuff users and non 
users age matched
ML, PD, DC
a Length of follow-up period for experimental studies, period of follow-up for prospective studies, and time study conducted otherwise
b DC = dental caries, ML = mucosal lesion, OP = oral pain, PD = periodontal or gingival diseases
c Brand A 0.8–0.9% nicotine, 8.2–8.5 pH; Brand B 0.4–0.5% nicotine, 7.8–8.2 pH
d Brand A 0.8% nicotine, 8.6 pH; Brand B 0.8% nicotine, 8.0 pH; Brand C 0.4–0.5% nicotine, 8.0 pH
e Women were also studied but none used snuff
Table 1: Details of European studies considered. (Continued)BMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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Table 2: Details of US studies considered.
First author, 
year of 
publication
Location Study Perioda Sex Age Population Further details 
of study design
Endpointsb
Experimental studies
Grasser 1997 [21] North Carolina 10 days M+F 18 to 47 214 soldiers 4 ST users with 
oral leukoplakia 
advised to stop
ML
Payne 1998 [22] Nebraska, Iowa 7 days M Mean 25 16 snuff users with 
oral lesions at 
habitual sites only
Site of snuff 
placement changed
ML
Martin 1999 [23] Texas 6 weeks M 17 to 34 3051 air force 
trainees
119 ST users with 
oral leukoplakia 
ordered to stop
ML
Prospective studies
Beck 1995 [24] North Carolina 1988 to 1991 M+F 65+ 818 dentate adults 
(50% black, 50% 
white)
Selected from 
Piedmont study. 
Reexamined at 18 
and 36 months
PD, OP
Dietrich 2007 [25] National 1986 to 2002 M 40–75 43112 health 
professionals 
dentate and cancer 
free at baseline
Data on tooth loss 
recorded every 2 
years
DC
Case-control studies
Fisher 2005A [26] West Virginia 2001 to 2002 M+F 18+ 90 cases of oral 
leukoplakia, 78 
controls with 
periapical cysts and 
no oral leukoplakia
Subjects identified 
from biopsy of 
hyperkeratosis
ML
Cross-sectional studies of populations unselected by ST use
Greer 1983 [27] Colorado Not given M+F 14 to 19 1119 high school 
students
-M L ,  P D ,  D C
Poulson 1984 [28] Colorado Not given M+F 14 to 19 Mean 16.7 445 high school 
students
-M L ,  P D ,  D C
Offenbacher 1985 
[29]
Georgia Not given M 10 to 17 Mean 13.8 565 grammar and 
high school 
students
-M L ,  P D ,  D C
Wolfe 1987 [30] New Mexico Not given M+F 14 to 19 Mean 16.0 226 Native 
American children 
at boarding school
-M L ,  P D
Cummings 1989 
[31]
New York 1985 M 22 to 44 Mean 29 25 baseball players 
and coaches
-M L ,  P D
Creath 1988 [32] Alabama Not given M 11 to 18 995 adolescent 
football players
-M L ,  P D
Stewart 1989 [33] Florida Not given M 10 to 18 114 middle and 
high school 
students
5588 M+F 
interviewed, 182 
examined orally, no 
results for 68F
ML
Ernster 1990 [34]c Arizona 1988 M+F 20 to 29 (77%) 1109 professional 
baseball players
-M L ,  P D ,  D C
Greene 1992 [35] Arizona 1989 to 1990 M 20 to 29 (76%) 894 professional 
baseball players
-M L
Sinusas 1992 [36] Pennsylvania 1990 M 17 to 58 Mean 25 206 baseball 
players and 
managers
-M L ,  P D ,  D CBMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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which may be equivalent to current). Fourteen of the US
studies provided evidence on snuff use. Ignoring one
study where the subjects were selected as having a lesion
[22], lesion prevalence in current snuff users was typically
in the range 30–70%, though lower in two studies [45,47]
where the definition implied a more severe lesion, and in
one study [31] where the endpoint of "soft tissue lesion"
was not further defined. Though lower than the near
100% prevalence reported in Scandinavia, it was clearly
much higher than in non-users, with ORs ranging from
8.2 to 97.1 in six studies [23,26,34-36,39]. In contrast the
evidence of any increased prevalence in former snuff users
is much weaker, with one case-control study [26] report-
ing no increase, one cross-sectional study [39] an increase
Daughety 1994 
[37]
Iowa Not given M 16 to 17 821 11th and 12th 
grade school 
students
-M L
Robertson 1997 
[38]
Arizona 1988 to 1990 M 20 to 29 (77%) 1846 professional 
baseball players
Includes subjects in 
Ernster 1990 [34] 
and Greene 1992 
[35]
ML, PD, DC
Tomar 1997 [39]d National 1986 to 1987 M+F 12 to 17 17027 school 
students
NIDR National 
Survey of Oral 
Health
ML
Tomar 1999 [40] National 1988 to 1994 M+F 18+ 14087 dentate 
adults
Third National 
Health and 
Nutrition 
Examination Survey 
(NHANES III)
DC
Riley 2004 [41] Florida 1993 to 2000 M+F 45+ 873 adults Reinterviews 
occurred over a 48 
month period but 
analyses are all 
cross-sectional
OP
Shulman 2004 [42] National 1988 to 1994 M+F 18+ 17235 adults NHANES III, but 
different endpoints 
from Tomar 1999 
[40]
ML
Fisher 2005B [43] National 1988 to 1994 M+F 18+ 12932 adults NHANES III, but 
different endpoints 
from Tomar 1999 
[40] and Shulman 
2004 [42]
PD
Sinusas 2006 [44] Pennsylvania 1991 to 2000 M Mean 26 190 to 259 baseball 
players and 
coaches examined 
each year
Men attending 
spring training. 
Some men may 
attend on multiple 
occasions
ML
Cross-sectional studies of populations selected by ST use and/or presence of oral lesions
Smith 1970 [45] Tennessee Not given M+F Mean 55 15000 long-term 
snuff users
-M L
Christen 1979 [46] Texas Not given M 18 to 22 Mean 20 14 college athletes 
who used ST
-M L ,  P D
Kaugars 1992 [47] Virginia Not given M 14 to 77 Mean 29 347 ST users 
recruited by 
advertisinge
-M L
Little 1992 [48] Oregon, 
Washington
Not given M 15 to 77 245 ST users in 
Kaiser Permanente 
Dental Care 
Program
Also 223 age-
matched non ST 
users
ML
Roberts 1997 [49] Indiana 1994 to 1995 M+F Not given 22 snuff users and 
19 non users
Oral lesions not 
recorded in non 
users
ML
a Length of follow-up period for experimental studies, period of follow-up for prospective studies, and time study conducted otherwise
b DC = dental caries, ML = mucosal lesion, OP = oral pain, PD = periodontal or gingival diseases
c Similar results are reported by Grady et al [83], Robertson et al [84] and Daniels et al [85]
d Results from this study are also reported by Kleinman et al [86]
e An additional group of 91 non users of ST with no oral lesions provides no useful information and has been ignored
Table 2: Details of US studies considered. (Continued)BMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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of borderline significance, another cross-sectional study
[31] an increase, but based on very few subjects, and one
experimental study [23] reporting resolution of the great
majority of lesions in US Air Force trainees after 6 weeks
of a mandatory tobacco-free period.
Nine of the US studies provided evidence on use of CT,
and in all of these lesion prevalence was lower in current
users of CT than in current users of snuff. Indeed in the
five studies where RRs and CIs could be estimated, risk
was not elevated (OR 0.97) in one study [26], was ele-
vated but not significantly (ORs 3.39 and 3.16) in two
studies [23,36] and was only significantly elevated (ORs
15.0 and 2.5) in two [34,39]. Oral mucosal lesion preva-
lence was not significantly associated with former CT use
[26,39].
Nineteen of the studies provided evidence on overall ST
use; in ten of these data by specific type of ST were not
available. Given the variation that could have existed in
the type of ST used in the different studies (and in the end-
points considered), it is not surprising that there is also
marked variation in the prevalence of oral mucosal
lesions reported in the different studies. However, it is
abundantly clear that there was a marked effect of use on
lesion prevalence. Thus, all of the studies for which ORs
(with CIs) could be estimated for current or ever ST use
showed a significant increase, with ORs over 25 in three
studies [21,23,34,48] and the lowest OR, 3.90, being in a
study [42] where the endpoint was wide ranging and prev-
alence relatively high in non-users. Again, the evidence of
an association was much weaker for former than for cur-
rent users. Of the six studies reporting relevant data, five
[26,34,36,38,42] found no relationship, with a significant
increase in former ST users reported only in one [44].
Aspects of the dose-response relationship have been
examined in many of the US studies. In one detailed anal-
ysis [34], odds ratios compared to non-users of ST
increased significantly with increasing amount of ST used,
hours in the month, and recency of last use, with esti-
mates of 354 (129–970) for users of four or more cans of
snuff a week, 34.7 (9.4–128) for users of four or more
pouches of CT a week, 361 (107–1215) for more than
four hours ST use in the day and 201 (84-9-475) for used
ST in the last hour. These associations were all found to be
independently significant in a multifactorial analysis, but
weaker associations with age of initiation and duration of
ST use were not independent risk factors. The findings
were unaffected by adjustment for age, race, education,
cigarette smoking, alcohol consumption, and dental
hygiene.
Though not usually analyzed in such detail, similar find-
ings have been reported by other authors. In users of ST or
of snuff, prevalence of oral lesions has consistently been
found to increase with increasing amount used and/or fre-
quency of use [23,27,28,30,32,35,39,48] and with
recency of use [23,35]. These studies also found that prev-
alence increased with duration of use, though they gener-
ally did not test whether the effect of duration remained
after adjustment for extent of current usage. Relationships
of severity of oral lesions to extent and duration of usage
have also been found [23,48], though not always [30].
The epidemiological data from Europe and the USA are
consistent with demonstrating a striking and dose-related
effect of current snuff use on the prevalence of oral
mucosal lesions. In Scandinavia, snuff users have a near
100% prevalence of SIL, but the prevalence of the more
varied lesions studied in the USA is typically lower. The
Table 3: Definitions of oral mucosal lesions used in studies in Scandinavia
Definition of Axéll 1976 [15]
Snuff dipper's lesion is a lesion of the oral mucosa at the exact site of the regular placing of snuff. The clinical appearance is graded as follows:
Degree 1. A superficial lesion with a colour similar to the surrounding mucosa, and with slight wrinkling. No obvious mucosal thickening.
Degree 2. A superficial, whitish or yellowish lesion with wrinkling. No obvious thickening.
Degree 3. A whitish-yellowish to brown, wrinkled lesion with intervening furrows of normal mucosal colour. Obvious thickening.
Degree 4. A marked, white-yellowish to brown and heavily wrinkled lesion with intervening, deep and reddened furrows and/or a heavy thickening.
Studies using the Axéll 1976 definition
Larsson 1991 [1], Andersson 1995 [2], Andersson 2003 [3], Roosaar 2006 [4], Rosenquist 2005 [5], Axéll 1976 [15], Hirsch 1982 [16], Salonen 
1990 [8]a, Andersson 1989 [18], Andersson 1994 [19] and Rolandsson 2005 [20]
Studies using other definitions
Jungell 1985 [7] – "snuff-induced lesion", not further defined
Pindborg 1963 [13] – "snuff-induced leukoplakia", characterised by a mucous membrane with "a slightly whitish, sometimes yellowish-brown dry 
appearance with a very delicately folded or finely grooved appearance"
Roed-Peterson 1973 [14] – "oral leukoplakia", defined as "a white patch not less than 5 mm in diameter which cannot be removed by rubbing, and 
which cannot be ascribed to any other diagnosable disease"
Frithiof 1983 [17] – "snuff-induced lesion", with "a characteristic whitish appearance frequently with a brown discolouration which clearly 
contrasted with the neighbouring mucosa"
a 32 other types of oral mucosal lesion were also considered, but results were incompletely presented and their incidence (not shown in Table 4) 
did not appear to be clearly snuff relatedBMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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association between current CT use and lesion prevalence,
mainly studied in the USA, is clearly very much weaker.
The lack of any very clear association with former use is
consistent with reversibility of the lesion following cessa-
tion, and fits in with findings from the experimental stud-
ies, which typically show regression of the lesion on
quitting after a relatively short period.
Periodontal and gingival diseases
A variety of indices relevant to periodontal and gingival
diseases are considered here, as illustrated in the endpoint
column for Tables 7 and 8, where the results relating to ST
use are given. Table 7 summarizes findings from seven
studies in Sweden, no other Scandinavian studies report-
ing results, while Table 8 gives results from 13 studies in
the USA. Changing and inconsistent diagnostic criteria, as
well as a lack of standardized use of methods and termi-
nology [76-81] complicate the summarizing of evidence
in this area. The endpoints in Tables 7 and 8 are as named
by the authors of the original publications cited, and are
defined more precisely there. The results are sorted so that
similar endpoints are classified together, in order to facil-
itate the interpretation of the data. Some of the endpoints
considered, such as plaque and calculus, do not of them-
selves indicate disease, but are indirectly related and the
results are shown for additional information.
The results from Sweden show no significant relationship,
in any study, between snuff use and the presence of
plaque or calculus, pocket depth, attachment loss, alveo-
Table 4: Prevalence of oral mucosal lesions in relation to snuff use evidence from Scandinavia
Study Location Summary of main results
Experimental studies
Larsson 1991 [1] Sweden Of 29 users with degree 2 to 4 lesions, the lesion disappeared in 20 who quit snuff or changed to portion-
bags and changed placement of the quid, reduced in 7 who changed to portion-bags and reduced their 
exposure, and remained in 2 who modified their habits only slightly.
Andersson 1995 [2] Sweden 100% lesion prevalence initially in 24 users of ordinary snuff and in 18 users of low nicotine snuff. After 2 
weeks, severity was non-significantly lower in habitual users of low nicotine brand. After a further 10 
weeks, switching to the low nicotine brand was associated with a reduction in lesion severity (p < 0.01), 
despite an increased intake of 2.5 g/day.
Andersson 2003 [3] Sweden The 20 users of brand A (0.8% nicotine, pH 8.6) had a severity distribution of 0/0/16/4 for degrees 1/2/3/4 
respectively. Switching to brand B (0.8% nicotine, pH 8.0) for 12 weeks, reduced the severity to 0/7/13/0, 
and switching to brand C (0.4–0.5% nicotine, pH 8.0) reduced it further to 2/11/7/0.
Prospective studies
Roosaar 2006 [4] Sweden Of 176 users with grade 1–4 lesions in 1973–1974 who were re-examined in 1993–1995, the lesion had 
disappeared in 62/66 = 94% of those who stopped, and remained in 108/110 = 98% of whose who 
continued (p < 0.001). Grade 3 and 4 lesions were less common in those who switched to portion-bag 
snuff, 6/42 = 14%, than in those who continued with loose snus, 20/68 = 29% (0.05 < p < 0.1).
Case-control studies
Rosenquist 2005 [5] Sweden 100% lesion prevalence in 31 population controls who currently used snuff. Lesion severity was significantly 
associated with hours/day consumed (p = 0.01), but not with daily consumption (p = 0.07), or duration of 
use (p = 0.8).
Cross-sectional studies of populations unselected by ST use
Jungell 1985 [7] Finland 63.6% lesion prevalence in 33 snuff users examined. Of the 12 with no lesions, 8 had quit snuff and 4 
started snuff in the previous 3 weeks.
Salonen 1990 [8] Sweden 92 lesions in 58 snuff only users, 29 in 23 mixed smokers and snuff users, 5 in 235 smokers and 0 in 602 
with no tobacco habit (frequencies of subjects with lesion not given).
Cross-sectional studies of populations selected by ST use and/or presence of lesions
Pindborg 1963 [13] Denmark 100% lesion prevalence in 12 long-term snuff users (lesion prevalence probable inclusion criterion).
Roed-Peterson 1973 [14] Denmark Among 450 selected patients with oral leukoplakia, the 32 who used snuff experienced fewer symptoms 
than the other 418 patients.
Axéll 1976 [15] Sweden Among 108 selected snuff users with oral lesions, severity increased with consumption (hours/day or 
grams/day) of snuff.
Hirsch 1982 [16] Sweden 100% lesion prevalence in 50 habitual snuff users (lesion prevalence probable inclusion criterion). Severity 
increased with consumption (hours/day or grams/day) of snuff, and also with duration of use.
Frithiof 1983 [17] Sweden Among 21 snuff users referred for treatment due to oral lesions, those who quit following advice to do so 
had marked lesion improvement in two weeks.
Andersson 1989 [18] Sweden 100% lesion prevalence in 252 snuff users. Severity was significantly less in 68 users of portion-bag snuff 
than in 184 users of loose snuff. Severity was also clearly associated with consumption (hours/day or 
grams/day), though less clearly with duration of use.
Andersson 1994 [19] Sweden 100% lesion prevalence in 45 snuff users. Severity was less in 23 users of portion-bag snuff than in 22 users 
of loose snuff.
Rolandsson 2005 [20] Sweden Lesion prevalence 87.5% in 40 snuff users and 0.0% in 40 non-users (p < 0.001). Prevalence and severity 
increased with hours/day of snuff and was lower in users of portion-bag snuff.BMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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lar bone level, bone height or periodontal disease
(defined as three or more teeth with pocket depth ≥ 5
mm). One study [6] reported that snuff users had a signif-
icantly (p < 0.001) increased gingival index, but other
studies [10-12,20] showed no relationship with gingivitis,
gingival index or gingival bleeding. Gingival recession was
considered by five Swedish studies. Two of these [17,20]
provided no data for non-users of snuff, but of the others,
one [10] reported the highest rates of recession, but no
significant increase in relation to ever snuff use, one [12]
reported a significant increase (OR 3.72, 95% CI 1.40–
9.99), and one [18] reported a significantly (p < 0.05)
higher prevalence in users of loose snuff than portion-bag
snuff.
The two US studies to provide some data relating to use of
CT [31,34] found no evidence of a relationship with
plaque, gingival bleeding or attachment loss, though one
of these [31] reported a non-significant increase for gingi-
val recession. However, some of the studies found a rela-
tionship between snuff or unspecified ST with some
indices of periodontal or gingival diseases. While no sig-
nificant increases were seen for plaque, calculus, gingivi-
tis, gingival bleeding or pocket depth, the data, though
somewhat inconsistent, suggested a relationship with gin-
gival recession. Here, six studies provide relevant data,
three in children or adolescents [29,30,32] and three in
baseball players [31,34,38]. The two which reported very
low rates of gingival recession [30,32] found no associa-
tion, but four [29,31,34,38] did, significant except in the
case of one small study [31]. One of the studies [29]
reported high rates of recession and a strong relationship
(OR 9.15, 95% CI 5.40–15.5), even stronger in patients
with gingivitis. Two studies [24,34] also reported a signif-
Table 5: Definitions of oral mucosal lesions used in studies in the USA
Definition of Greer 1983 [27]
Modified version of Axéll 1976 [15]. Oral mucosal lesion graded for severity as:
Degree 1. A superficial lesion with colour similar to that of the surrounding mucosa with slight wrinkling and no obvious thickening.
Degree 2. A superficial whitish or reddish lesion with moderate wrinkling and no obvious thickening.
Degree 3. A red or white lesion with intervening furrows of normal mucosal coour, obvious thickening and wrinkling.
Studies using the Greer 1983 definition
Payne 1998 [22], Greer 1983 [27], Poulson 1984 [28], Wolfe 1987 [30], Stewart 1989 [33], Sinusas 1992 [36], Sinusas 2006 [44] and Little 1992 
[48].
Studies using other definitions
Grasser 1997 [21] – oral leukoplakia; a white patch or plaque that does not wipe off and cannot be characterized clinically or pathologically as any 
other disease
Martin 1999 [23] – oral leukoplakia; modified from Greer 1983 definition, graded for severity as 1: superficial lesion with slight colour change, slight 
wrinkling and no obvious thickening, 2: superficial white lesion with moderate wrinkling and no obvious thickening, and 3: white lesion with obvious 
thickening and wrinkling
Fisher 2005 [26] – oral leukoplakia; based on the international classification of diseases, 9th revision code (ICD-9) of 528.6 with a biopsy of 
hyperkeratosis with or without epithelial atypia or dysplasia. A clinical diagnosis of ST keratosis or frictional keratosis was excluded
Offenbacher 1985 [29] – oral mucosal pathology; alterations considered to represent early changes, as reflected by a mild increase in opalescence 
and whiteness, with slight furrowing
Creath 1988 [32] – oral leukoplakia; not further defined
Cummings 1989 [31] – soft tissue lesions; not further defined
Ernster 1990 [34] and Greene 1992 [35] – oral leukoplakia; any white, opaque, leathery-appearing plaque not clinically characteristic of another 
type of white lesion, graded for severity as 1: no or only slight colour change, with or without texture change, 2: colour and texture change, but no 
thickening, 3: colour and texture change with mild to moderate thickening, or 4: no normal colour, severe texture change, and heavy thickening
Daughety 1994 [37] – oral lesions at placement site; from response to question "Have you ever noticed a sore, white patch or gum problem where 
you held the tobacco in your mouth?"
Robertson 1997 [38] – oral leukoplakia; any white, opaque, leathery-appearing slightly raised, and irregularly corrugated changes in the oral mucosa 
not characteristic of another white lesion, graded for severity from 1: slight change in colour and texture to 4: no normal colour, severe texture 
change and heavy thickening
Tomar 1997 [39] – ST lesions; slight to heavy wrinkling of the mucosa with or without obvious thickening, graded for severity as 1: slight, superficial 
wrinkling of the mucosa. Colour of the mucosa may range from normal to pale white or grey. Mucosa does not appear to be thickened, 2: distinct 
whitish, greyish, or occasionally reddish colour change. Wrinkling is obvious, but there is no thickening of the mucosa, or 3: mucosa is obviously 
thickened, with distinct whitish or greyish colour change. Deep furrows are present within the thickened areas
Shulman 2004 [42] – oral mucosal lesions; 49 types of lesion are listed, including candida-related lesions, tobacco-related lesions, acute conditions 
and various other conditions, but ST use is only given in relation to the overall incidence of any type
Smith 1970 [45] – oral mucous membrane change "which offered criteria for further study"
Christen 1979 [46] – clinical leukoplakia; a white plaque on the mucosa, with mild to moderate defined as a non palpable, smooth, fairly translucent 
white area, and severe defined as areas appearing thick, white, indurated and fissured
Kaugars 1992 [47] – oral lesion; a visible alteration of the oral mucosa that persisted for at least 7 days after discontinuation of ST use; an alteration 
with little probability of resolving within 7 days, in the opinion of the investigator, or an alteration occurring in a subject who was unable to return 
for a recall visit
Roberts 1997 [49] – oral lesion; any visible lesionBMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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Table 6: Prevalence of oral mucosal lesions in relation to ST use – evidence from the USA
% prevalence (n)a
Study Endpointb Exposurec Exposed Unexposed Statistical tests and other results 
and commentsd
Experimental studies
Grasser 1977 [21] Oral leukoplakia ST ever 13.3 (4) 0.5 (1) OR 28.2 (3.03–262)
Lesions in users resolved after 10 days 
quit
Payne 1988 [22] Greer 1–3 Snuff current 100.0 (16)e - After switching site of snuff placement 
and to reference snuff, all 16 subjects had 
new lesions after 7 days of use, evident in 
15 subjects by day 2. After 7 days, the 
original lesions at the habitual sites had 
resolved by 1 degree
Martin 1999 [23] Oral leukoplakia ST current 39.4 (119) 1.5 (42)f OR 41.9 (28.6–61.4)
Snuff current 41.8 (118) 1.5 (42)f OR 46.4 (31.5–68.2)
CT current 5.0 (1) 1.5 (42)f OR 3.39 (0.44–25.9)
Lesion had completely resolved in 97.2% 
(106/109) of ST users 6 weeks after 
tobacco use was prohibited
Case-control studies
Cases Controls
Fisher 2005 [26] Oral leukoplakia ST current 22.5 7.2 OR 9.21 (1.49–57.0)g
ST former 25.7 12.3 OR 2.73 (0.69–10.8)g
Snuff current 19.0 2.7 OR 30.1 (2.67–338)g
Snuff former 11.1 6.6 OR 0.98 (0.17–5.61)g
CT current 4.2 4.3 OR 0.97 (0.19–4.98)
CT former 20.0 12.0 OR 1.83 (0.76–4.40)
Cross-sectional studies of populations unselected by ST use
Exposed Unexposed
Greer 1983 [27] Greer 1–3 ST use 42.7 (50) - Only ST users examined
Poulson 1984 [28] Greer 1–3 ST use 58.9 (33) - Only ST users examined
Offenbacher 1985 [29] Oral mucosal pathology ST use 22.7 (17) 4.7 (23) OR 5.95 (3.00–11.8)
Wolfe 1987 [30] Greer 1–3 ST currenth 25.5 (37) 3.7 (3)f OR 8.91 (2.65–29.9)
Creath 1988 [32] Oral leukoplakia Snuff ever 5.2 (15) 0.1 (1) OR 38.6 (5.07–294)
Cummings 1989 [31] Soft tissue lesion ST current 17.6 (3) 0.0 (0) Only 6 never users of ST No differences 
significant
ST former 100.0 (2) 0.0 (0)
Snuff current 21.4 (3) 0.0 (0)
CT current 11.1 (1) 0.0 (0)
Stewart 1989 [33] Greer 1–3 ST current 29.0 (9) - Prevalence only reported for male 
current users
Ernster 1990 [34] Oral leukoplakia ST current 46.3 (196) 1.4 (7) OR 59.9 (27.8–129)
ST formerj 1.7 (3) 1.4 (7) OR 1.19 (0.30–4.65)
Snuff currentk 58.3 (165) 1.4 (7) OR 97.1 (44.4–212)
CT currentk 17.7 (14) 1.4 (7) OR 15.0 (5.82–38.4)
Greene 1992 [35] Oral leukoplakia ST current 51.7 (167) 2.9 OR 35.8i
ST formerj 3.5 2.9 OR 1.21i
Snuff currentk 61.3 (157) 2.9 OR 53.0i
CT currentk 14.8 (8) 2.9 OR 5.82i
Sinusas 1992 [36] Greer 1–3 ST current 37.1 (23) 6.0 (5) OR 9.32 (3.29–26.4)
ST formerl 6.7 (4) 6.0 (5) OR 1.13 (0.29–4.39)
Snuff currentk 34.2 (13) 6.0 (5) OR 8.22 (2.67–25.3)
CT currentk 16.7 (4) 6.0 (5) OR 3.16 (0.78–12.9)
Daughety 1994 [37] Oral lesions at placement site ST current 33.0 (45) - Only ST users asked about oral lesionsBMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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icant association of snuff or ST with attachment loss,
though another study [30] reported no significant rela-
tionship. Of two studies of periodontal diseases (see foot-
notes to Table 8 for definitions), one [36] found no
relationship with ST use, but the other [43] reported a sig-
nificant increase in current users.
Based on the overall data from the US and Sweden, the
evidence of a relationship with snuff or unspecified ST use
is weak for gingivitis (or gingival bleeding), where a signif-
icant association is reported in only one out of eight stud-
ies, and for the more general term periodontal disease,
where one of the three studies found a relationship. It is,
however, rather stronger for attachment loss, where signif-
icant associations were reported in two out of four studies,
and particularly for gingival recession, where four out of
eight studies reported a significant relationship, and an
additional study [18] found that prevalence was almost
nine times higher in loose snuff users than in portion-bag
snuff users. Very limited evidence for CT did not demon-
strate any relationship with periodontal or gingival dis-
eases.
Dental caries
Table 9 (Sweden) and Table 10 (USA) summarize results
relating ST use to presence of teeth and indices of dental
Snuff current 43.9 (25) -
Robertson 1997 [38] Oral leukoplakia ST current ≈50 < 2 Approximate estimates based on 1846 
baseball players in various studies
ST former < 2 < 2
Tomar 1997 [39] ST lesions Snuff current 34.9 (107)m 1.9 (102)m OR 18.4 (8.5–39.8)n
Snuff former 5.6 (18)m 1.9 (102)m OR 2.4 (1.0–6.1)n
CT current 19.6 (54)m 3.0 (156)m OR 2.5 (1.3–5.0)o
CT former 6.0 (32)m 3.0 (156)m OR 1.3 (0.7–2.2)o
Shulman 2004 [42] Oral mucosal lesions ST currentp 60.3 (224) 23.8 (1939) OR 3.90 (2.75–5.55)q
ST formerp 12.8 (23) 23.8 (1939) OR 0.53 (0.25–1.13)q
Sinusas 2006 [44] Greer 1–3 ST current 27.9–46.3r 4.0 p < 0.001
ST former 9.5 4.0 p < 0.001
Cross-sectional studies of populations selected by ST use and/or presence of oral lesions
Smith 1970 [45] Oral mucous membrane change Snuff current 11.7 (1751) - Only snuff users examined
Christen 1979 [46] Clinical leukoplakia ST current 64.3 (9) - Only ST users examined
Snuff current 69.2 (9) -
CT current 57.1 (4) -
Kaugars 1992 [47] Oral lesions ST currents 13.0 (45) - Only ST users examined
Snuff currents 14.4 (34) -
CT currents 8.4 (18) -
Little 1992 [48] Greer 1–3 ST current 78.8 (193) 6.3 (14)t OR 55.4 (29.8–103)
Roberts 1997 [49] Oral lesion Snuff current 31.8 (7) - Only snuff users examined
a n = number of subjects with endpoint
b See Table 5 for further definition of endpoint
c Where possible exposure is classified as "current" or "former" with exposure given as "use" only where the source paper did not clearly 
distinguish how former users were considered. The corresponding non-exposure is "never" or "non-use" to the same type of ST, except where 
indicated
d ORs are unadjusted for potential confounding variables, except where stated. Where necessary ORs and 95% CIs are calculated from the data 
provided in the source paper
e Subjects selected to have a lesion at site of snuff placement
f Unexposed group is non-current ST
g Adjusted for age, sex, smoking, alcohol, dental prostheses
h Within the last 7 months
i Numbers of never and former users not available so CI cannot be calculated
j Former includes current in last month but not in last week
k Product usually used
l Former includes those who only used ST in baseball season (study conducted out of season)
m Percentages are based on weighted data; numbers of cases are approximate, calculated by multiplying sample size by weighted percentage
n Adjusted for age, cigarettes, alcohol and CT
o Adjusted for age, cigarettes, alcohol and snuff
p Analyses compare ST users who do not smoke with never users of any tobacco
q Adjusted for age, sex, race and denture use
r Prevalence in current users given only as range over the course of the 10 year study
s Within the past 12 months
t Comparison is with non ST users
Table 6: Prevalence of oral mucosal lesions in relation to ST use – evidence from the USA (Continued)BMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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caries. They are laid out in a style similar to Tables 7 and
8, with results grouped according to the endpoints consid-
ered. Endpoints in Tables 9 and 10 are named as in the
original publications cited here, with the reader referred to
these publications for further definition.
Two studies from Sweden [11,20] provided no indication
of an effect of snuff use on the number of teeth present.
One of these studies [20] also reported no relationship
with having filled teeth. The third study [9], of 14–19 year
olds attending dental check-up, reported significant (p <
0.001) increases in snuff users in the mean number of
decayed, missing and filled teeth, of decayed and filled
proximal surfaces and of initially decayed proximal sur-
faces, though not in the mean number of decayed proxi-
mal surfaces. It should be noted, however, that these
analyses were not adjusted for age, the snuff dippers being
markedly older (71% aged 17–19) than the non-tobacco
users (52% aged 17–19, p < 0.001). Within specific years
of age, significant differences were generally not seen
(except for decayed, missing and filled teeth in 17 year
olds), but an overall age-adjusted test was unfortunately
Table 7: Snuff use and endpoints relevant to periodontal and gingival disease – evidence from Sweden
Study Endpoint Time of exposure Statistic Exposeda Unexposeda Nb Summary of statistical 
testsc
Wickholm 2004 [10] Plaque index Ever % ≥ 2.0 2.6 2.0 4 OR 1.29 (0.45–3.70)d
Montén 2006 [12] Plaque Current % 59.0 64.0 19 OR 0.75 (0.32–1.76)
Wickholm 2004 [10] Calculus index Ever % ≥ 2.0 5.9 3.8 9 OR 1.57 (0.76–3.23)d
Montén 2006 [12] Gingivitis Current % 47.0 50.0e 16 OR 0.94 (0.41–2.15)
Modeer 1980 [6] Gingival index Not known mean 1.10 0.89 - p < 0.001f
Rolandsson 2005 [20] Gingival index Current mean 12.4 13.1 - Difference not significant
Wickhol m 2004 [10] Gingival index Ever % ≥ 2.0 8.5 12.0 13 OR 0.68 (0.38–1.22)d
Rolandsson 2005 [20] Gingival bleeding Current % 10.0 20.0 4 OR 0.44 (0.12–1.62)
Bergström 2006 [11] Gingival bleeding Current - - -e - No significant difference
Former - - -e - No significant difference
Frithiof 1983 [17] Gingival recession Current % 9.5 - 2 -
Andersson 1989 [18] Gingival recession Currentg % 17.8 - 44 Prevalence higher in loose 
snuff users (23.5%) than in 
portion-bag users (2.9%), p < 
0.05
Wickholm 2004 [10] Gingival recession Ever % 64.7 59.9 99 OR 1.22 (0.87–1.73)d
Rolandsson 2005 [20] Gingival recession Current % 17.5 - - -
Montén 2006 [12] Gingival recession Current % 42.0 17.0 14 OR 3.72 (1.40–9.99)h
Wickholm 2004 [10] Pocket depth Ever %≥ 5 mm 10.5 9.5 16 OR 1.11 (0.64–1.92)d
Bergström 2006 [11] Pocket depth Current - - -e - No significant difference
Former - - -e - No significant difference
Montén 2006 [12] Pocket depth Currentg mean 2.3 2.4 - No significant difference
Montén 2006 [12] Attachment loss Currentg mean 0.2 0.1 - No significant difference
Montén 2006 [12] Alveolar bone level Currentg mean 1.3 1.3 - No significant difference
Bergström 2006 [11] Bone Heightj Current mean 1.0 1.06e - No significant differencei
Former mean 1.12 1.06e - No significant differencei
Wickholm 2004 [10] Periodontal diseasel Current - - - - OR 0.66 (0.30–1.32)k
Former - - - - OR 2.55 (0.80–6.80)k
a Exposure is always to snuff and is classified, where possible, as current or former. The corresponding unexposed group is never for ever, and non-
current for current, except where indicated
b Number of exposed subjects with endpoint (where available)
c Tests are unadjusted for any potential confounding variable, except where stated. Where necessary ORs and 95% CIs are calculated from the data 
provided in the source paper
d The source paper presented results separately for four groups: A = never used tobacco, B = smoked only, C = snuff only, D = smoked and snuff. 
The ORs given in Table 7 are based on combining ORs for nonsmokers (C vs A) and smokers (D vs B) using fixed-effects meta-analysis [87], and 
are thus adjusted for smoking. ORs (CIs) specifically for nonsmokers are plaque index 1.13 (0.14–9.11), calculus index 3.53 (0.93–13.45), gingival 
index 1.14 (0.39–3.33), gingival recessions 1.43 (0.80–2.55) and pocket depth 1.61 (0.54–4.80)
e Unexposed is never snuff
f Adjusted for plaque index
g Snuff only, no smoking
h The ORs and CIs are adjusted for plaque, gingivitis and toothbrushing
i Adjusted for age
j Distance from the cement-enamel junction to the periodontal bone crest
k Adjusted for smoking and plaque index
l Three or more teeth with pocket depth ≥ 5 mmBMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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Table 8: ST use and endpoints relevant to periodontal and gingival disease – evidence from the USA
Study Endpoint Time of exposure Statistic Exposeda Unexposeda Nb Summary of statisti-
cal testsc
Ernster 1990 [34] Plaque Snuff ever % 25.8 29.7d 154 OR 0.82 (0.65–1.03)
Ernster 1990 [34] Plaque CT ever % 30.2 29.7d 52 OR 1.02 (0.72–1.46)
Wolfe 1987 [30] Calculus ST current %e 21.6 20.5f - "Virtually no difference"
Offenbacher 1985 [29] Gingivitis ST use % 72.0 77.1 54 OR 0.76 (0.44–1.32)
Cummings 1989 [31] Gingivitis ST current % 35.3 33.3 6 OR 1.09 (0.15–7.80)
ST former % 50.0 33.3 1 OR 2.00 (0.08–51.6)
CT current % 33.3 33.3d 3 OR 1.00 (0.11–8.95)
Snuff current % 28.6 33.3d 4 OR 0.80 (0.10–6.25)
Robertson 1997 [38] Severe gingivitis ST current % - - - "Prevalence equally 
distributed"
ST former % - - - "Prevalence equally 
distributed"
Wolfe 1987 [30] Gingival bleeding ST current %e 6.2 7.1f - "Virtually no difference"
Ernster 1990 [34] Gingival bleeding Snuff ever % 5.9 8.8d 35 OR 0.64 (0.43–0.96)
Ernster 1990 [34] Gingival bleeding CT ever % 9.9 8.8d 17 OR 1.13 (0.65–1.96)
Offenbacher 1985 [29] Gingival recession ST use % 60.0 14.1 45 OR 9.15 (5.40–15.5)g
Wolfe 1987 [30] Gingival recession ST current mean %e 0.4 0.6f - "Virtually no difference"
Creath 1988 [32] Gingival recession Snuff ever % 0.3 0.0 1 No significant 
difference
Cummings 1989 [31] Gingival recession ST current % 41.2 16.7 7 OR 3.50 (0.33–36.9)
ST former % 50.0 16.7 1 OR 5.00 (0.15–167)
CT current % 55.6 16.7d 5 OR 6.25 (0.50–77.5)
Snuff current % 35.7 16.7d 4 OR 2.78 (0.25–30.9)
Ernster 1990 [34] Gingival recession Snuff ever % 26.4 13.8d 158 OR 2.24 (1.73–2.90)h
Ernster 1990 [34] Gingival recession CT ever % 11.0 13.8d 19 OR 0.77 (0.46–1.29)
Robertson 1997 [38] Gingival recession ST use % - - - ST users had 
"significantly more 
recession"
Christen 1979 [46] Gingival recession ST current % 50.0 - 7 -
Robertson 1997 [38] Gingival recession 
increase
ST use mean (mm) 0.36 No change - Not tested
Creath 1988 [32] Rolled gingival margins Snuff ever % 3.1 3.4 9 OR 0.91 (0.42–1.99)
Ernster 1990 [34] Pocket depth ST use % ≥ 4 mm - -d - No significant 
difference
Robertson 1997 [38] Pocket depth ST use % - - - No significant 
difference
Wolfe 1987 [30] Attachment loss ST current %e 3.9 3.3f - "Virtually no difference"
Ernster 1990 [34] Attachment loss Snuff ever % 10.7 4.4d 64 OR 2.63 (1.75–3.93)h
Ernster 1990 [34] Attachment loss CT ever % 4.7 4.4d 8 OR 1.07 (0.49–2.32)
Beck 1995 [24] Attachment loss (new 
lesions)i
ST use % - - - OR 2.99 (p = 0.001)j
Beck 1995 [24] Attachment loss (lesion 
progression)k
ST use mean - - - No associationl
Greer 1983 [27] Periodontal 
degenerationm
ST use % 25.6 - 30 -
Poulson 1984 [28] Periodontal 
degenerationm
ST use % 26.8 - 15 -
Sinusas 1992 [36] Periodontal diseasen ST use % 19.3 21.2 17 OR 0.89 (0.42–1.87)
Fisher 2005 [43] Periodontal diseaseo ST current % 9.8 4.3 29 OR 2.1 (1.2–3.7)p
Fisher 2005 [43] Periodontal diseaseo ST former % 9.1 4.3 38 OR 1.5 (0.9–2.6)pBMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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not reported. The analyses were also not adjusted for edu-
cation.
Tooth loss in relation to ST use was investigated in three
US studies. While one [38] found no association with ST
use, one [40] found a significant relationship with current
snuff but not current CT use, and the third [25] reported a
significant 14% increase in the rate of tooth loss in a large
prospective study in which adjustment was made for a
range of potential confounding variables, including age
and social status.
Dental caries was studied in seven US studies. In six of
these [27-29,34,38,44] there was no significant evidence
of a relationship with unspecified ST use. The seventh and
by far the most comprehensive investigation [40] was
based on the NHANES III study. Results for a range of the
endpoints studied are shown in Table 10. No significant
difference was seen for snuff use for any index of dental
caries (though, as noted above, it was for number of teeth
present). In contrast, CT use was significantly associated
with decayed or filled permanent teeth, decayed or filled
root surfaces, and decayed root surfaces. In an analysis
adjusted for age, race/ethnicity, education, and past-year
dental visits, the OR for decayed or filled root surfaces was
4.18 (1.96–9.92) for current users of CT only and 0.67
(0.26–1.74) for current users of snuff only, compared to
never users of tobacco. In current users of CT, the OR
increased with the number of packs per week (trend p =
0.0002) and with years of use (trend p = 0.002). None of
the other studies reported dose-response data for dental
caries.
Table 9: Snuff use and endpoints relevant to dental caries and tooth loss – evidence from Sweden
Study Endpoint Time of exposure Statistic Exposeda Unexposeda Summary of statistical 
testsb
Rolandsson 2005 [20] Teeth present Not known Mean 27.3 26.9 No significant difference
Bergström 2006 [11] Teeth present Current Median 29 28 No significant difference
Bergström 2006 [11] Teeth present Former Median 28 28 No significant difference
Rolandsson 2005 [20] Filled teeth Not known % any - - OR 1.91 (0.76–4.79)
Rolandsson 2005 [20] Filled teeth Not known Mean - - No significant difference
Hirsch 1991 [9] Decayed, missing and filled 
teeth
Not known Mean - - Increased in users (p < 
0.001)
Hirsch 1991 [9] Decayed proximal surfaces Not known Mean - - No significant difference
Hirsch 1991 [9] Decayed and filled proximal 
surfaces
Not known Mean - - Increased in users (p < 
0.001)
Hirsch 1991 [9] Initially decayed proximal 
surfaces
Not known Mean - - Increased in users (p < 
0.001)
a In the Rolandsson 2005 [20] study, snuff use was compared with snuff non-use; in the Bergström 2006 [11] study, current or former use was 
compared with never use; in the Hirsch 1991 [9] study, snuff use was compared with no tobacco use
b All statistical tests are unadjusted for any potential confounding variable. Where necessary ORs and 95% CIs are calculated from the data provided 
in the source paper
a Where possible exposure is classified as "current" or "former" with exposure given as "use" only where the source paper did not clearly 
distinguish how former users were considered. The corresponding non-exposure is never or non-use to the same type of ST, except where 
indicated
b Number of exposed subjects with endpoint (where available)
c Tests are unadjusted for any potential confounding variable, except where stated. Where necessary ORs and 95% CIs are calculated from the data 
provided in the source paper
d Unexposed is ST never
e % of sites affected
f Unexposed is ST non-current
g The OR for gingival recession is 20.7 if gingivitis is present and 1.13 if it is not present
h The authors also reported an increase in snuff users after adjustment for age, race, cigarette smoking, alcohol consumption and dental hygiene 
practice
i During the whole year follow-up period
j Adjusted for income, soft tissue reaction and history of pain
k Increase in depth over a one year period
l ST did not appear as an independent risk factor, following backward elimination, in a logistic regression model involving multiple sociodemographic, 
psychological, medical, environmental, behavioural and oral variables
m Defined as gingival recession with apical migration of the gingival to or beyond the cementoenamel junction, with or without clinical evidence of 
inflammation
n Gingival recession or gingival thickening and erythema
o Severe active periodontal disease, defined as having at least one tooth with 6 mm or more attachment loss, and bleeding in the same tooth
p Adjusted for smoking, age, diabetes, minority status, gender and visiting dentist in the past year. Similar estimates of 2.1 (1.0–4.4) for current ST 
and 1.5 (0.5–4.3) for former ST are given for never smokers, and of 2.1 (1.0–4.2) for current ST and 1.3 (0.7–2.7) for former ST are given for 
interproximal severe active periodontal disease
Table 8: ST use and endpoints relevant to periodontal and gingival disease – evidence from the USA (Continued)BMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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The overall evidence is suggestive of a possible relation-
ship of ST use, particularly CT, with the risk of dental car-
ies.
Oral pain
Information relating ST use to oral pain is extremely lim-
ited. In the Florida Dental Care Study [41], 33 adults aged
45+ were current users of CT or snuff, 69 were former
users, and 604 had never been users. Based on reports
over a 48 month period, analyses were carried out relating
current and former ST use to five pain variables (tooth
pain, painful gums, temperature sensitivity, activity reduc-
tion, and trouble sleeping because of oral pain), with
adjustment for race, sex, age, oral hygiene, dental care,
and education. Former use was unrelated to any of the five
pain variables. For current use, a significant increase was
noted for painful gums (OR 1.7, 95% CI 1.2–2.1), but not
for the other four variables, with the odds ratio for tooth
pain being 1.0 (95% CI 0.4–2.3). Separate results for CT
and for snuff were not presented.
No other study directly related ST to the prevalence of oral
pain, but a study in Denmark [14] found that among oral
leukoplakia patients, snuff users were less likely to experi-
ence pain from the lesion than were non-snuff users (1/32
= 3.1% vs 83/399 = 20.8%, p < 0.01). The North Carolina
Table 10: ST use and endpoints relevant to dental caries and tooth loss – evidence from the USA
Study Endpoint Time of Exposurea Statistic Exposed Unexposedb Summary of statistical 
testsc
Robertson 1997 [38] Teeth present ST use Mean - - No significant difference
Tomar 1999 [40] Teeth present CT current Mean 23.89 24.29 No significant differenced
Tomar 1999 [40] Teeth present Snuff current Mean 22.99 24.29 p < 0.005d
Dietrich 2007 [25] Tooth loss CT ever HR - - HR 1.14 (1.04–1.24)e
Greer 1983 [27] Dental caries ST use % 0.0 - "No evidence of dietary-
associated caries"
Poulson 1984 [28] Dental caries ST use % 0.0 - "Tobacco-associated dental 
caries ...was absent"
Ernster 1990 [34] Dental caries ST use % - - No significant difference
Sinusas 1992 [36] Dental caries ST use % 7.95 13.56 OR 0.55 (0.19–1.51)
Offenbacher 1985 [29] Decayed, missing and filled 
teeth
ST use Mean 4.05 3.32 0.05 < p < 0.1f
Robertson 1997 [38] Decayed or filled teeth ST use Mean - - Higher in users (significance 
unknown)
Tomar 1999 [40] Decayed or filled teeth CT current Mean 7.99 6.97 p < 0.05d
Tomar 1999 [40] Decayed or filled teeth Snuff current Mean 6.11 6.97 No significant differenced
Tomar 1999 [40] Decayed or filled coronal 
surfaces
CT current Mean 19.68 17.43 No significant differenced
Tomar 1999 [40] Decayed or filled coronal 
surfaces
Snuff current Mean 15.58 17.43 No significant differenced
Tomar 1999 [40] Decayed or filled root 
surfaces
CT current Mean 3.84 1.05 p < 0.005d
Tomar 1999 [40] Decayed or filled root 
surfaces
Snuff current Mean 0.86 1.05 No significant differenced
Tomar 1999 [40] Decayed or filled root 
surfaces
CT current % - - OR 4.18 (1.96–8.92)g
Tomar 1999 [40] Decayed or filled root 
surfaces
Snuff current % - - OR 0.67 (0.26–1.74)g
Tomar 1999 [40] Decayed root surfaces CT current Mean 3.24 0.88 p < 0.005d
Tomar 1999 [40] Decayed root surfaces Snuff current Mean 0.81 0.88 No significant difference
a In all studies except two, exposure is ST use unspecified as to whether current or ever. In Tomar 1999 [40] exposure is either current CT and no 
other form of tobacco, or current snuff and no other form of tobacco, and in Dietrich 2007 [25] exposure ever CT
b In all studies except two, comparison is with ST non-use. In Tomar 1999 [40] it is with never tobacco and in Dietrich 2007 [25] it is with never CT
c All statistical tests are unadjusted for any potential confounding variable, unless otherwise indicated. Where necessary ORs and 95% CIs are 
calculated from the data provided in the source paper
d Adjusted for age, and race or ethnicity
e Hazard ratio (HR) adjusted for age, other tobacco use, race, BMI, physical activity, diabetes, profession, routine medical examination, alcohol, 
calorie intake, multivitamin use and Vitamin C supplement use
f Estimated from means and standard errors given separately for subjects with and without gingivitis, between which groups no significant 
differences were seen associated with ST use
g Adjusted for age, race or ethnicity, education and past-year dental visitBMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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study [24] reported that ST use and history of pain both
predicted new cases of attachment loss over a three year
period but did not relate ST use to pain.
It is not possible to draw any clear conclusion on the rela-
tionship between ST use and oral pain from these data.
Discussion
This report is based on data from 50 studies published
between 1963 and 2007 relating the risk of non-neoplas-
tic oral diseases to the consumption of CT and snuff as
used in Europe (mainly Scandinavia) and the USA. Six
were experimental studies (or had an experimental com-
ponent); the epidemiological studies were mainly of
cross-sectional design. The number of studies considered
is substantially larger than in other recent reviews (e.g.
[66-71]). Many of the 50 reports have limitations and
present less information than is ideal. Problems encoun-
tered include small numbers of subjects or exposed cases,
unrepresentativeness of the studied populations, incon-
sistently defined outcomes, and heterogeneous methods
of exposure assessment. Exposure details such as type of
ST and duration and frequency of use were often not
reported. A number of the studies only presented data on
populations selected by ST use and/or presence of oral
lesions, and therefore, did not allow estimation of preva-
lences and odds ratios. At the analytical level, one major
weakness was incomplete presentation of findings.
Another was failure to adjust for important potential con-
founders, with only a handful of studies adjusting for var-
iables such as age, smoking, education or frequency of
dental visits. A third was the frequent failure to present
results separately for major subgroups, particularly regard-
ing alternative tobacco consumption, either smoked or
smokeless. Thus comparisons of ever snuff users with
never snuff users may also compare groups differing on
the use of cigarettes and other ST. These shortcomings
inevitably limit the inferences that can be drawn as well as
the possibility to conduct meaningful meta-analyses. Nev-
ertheless, we feel that it is possible to draw some conclu-
sions from the present results.
It is abundantly clear, as numerous reviewers agree [53-
55,59-71], that snuff use markedly increases the risk of
oral mucosal lesions. In Scandinavia, users have a near
100% prevalence of the characteristic SIL, a lesion which
appears not to occur in non-users, though direct evidence
from the available publications is limited to one study
[20]. In the USA, the types of lesion studied are much
more varied. There many snuff users do not have a lesion
and some non-users do, but prevalence is much higher in
users than in non-users, with reported odds ratios of up to
almost 100 [34], and frequency dose-related to daily
usage. Though strong dose-related relationships are also
clearly seen in relation to unspecified ST use, the associa-
tion between current CT use and lesion prevalence,
mainly studied in the USA, is clearly very much weaker.
In both the USA and Scandinavia prevalence of oral
mucosal lesions in former users of snuff, CT or unspeci-
fied ST is typically low and not clearly higher than in never
users, suggesting the reversibility of the effect. This is con-
sistent with the findings from experimental studies where
rapid regression upon quitting was observed as well as
rapid onset in subjects starting to use ST in the first place
or switching to a new habitual oral site. The experimental
studies also suggest that the severity (or even the appear-
ance) of the lesion can be affected by switching the type of
product used.
The rapid reversibility on quitting ST of SIL, and many of
the oral mucosal lesions studied in the USA, suggests that
presence of these lesions may not be of great clinical sig-
nificance. Additional evidence that there is a low proba-
bility of SIL transforming into oral cancer comes from the
recent follow-up study of Roosaar et al [4] which found no
cases of oral cancers at the site of snuff placement in over
1000 individuals with SIL followed for over 25 years, the
low incidence of oral cancer in Sweden, where use of oral
snuff is very common [64], and evidence that the lesions
induced may be less susceptible to malignant transforma-
tion than those induced by cigarette smoke [73]. While it
is well documented that cigarette smoking increases the
risk of oral cancer [72,82], a recent review of ST as cur-
rently used in Western populations suggests that it carries
little or no increased risk of oral cancer [57].
The evidence available for oral pain is too limited to draw
a clear conclusion regarding an association. Somewhat
more evidence is available (see Tables 5 to 8) regarding
periodontal diseases, caries and related conditions.
Although one study [6] reported a significantly higher
prevalence of gingivitis in snuff users in Sweden, a
number of other studies found no relationship of gingivi-
tis or gingival bleeding with the use of ST. Perhaps more
indicative of an effect is the evidence relating ST use to gin-
gival recession, attachment loss, dental caries and tooth
loss. For all four endpoints, however, the evidence is
somewhat inconsistent. From the data available, it is dif-
ficult to judge whether this variation is due to differences
in type of product used, different definitions of endpoints,
or failure to take into account other factors associated
with poor dental health, including age, smoking, socio-
economic status (education) and the number of visits to
the dentist. At present the evidence on attachment loss,
dental caries, and tooth loss must be regarded as no more
than suggestive of an association with the use of ST.
The evidence relating to gingival recession seems rather
stronger with four out of eight studies of snuff or unspec-BMC Oral Health 2008, 8:13 http://www.biomedcentral.com/1472-6831/8/13
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ified ST reporting a significant association. There is huge
variation in the reported prevalence between studies,
marked heterogeneity in the strength of the reported asso-
ciations in most of the studies reporting a relationship
(the extremely high odds ratio in one study [29] being
clearly inconsistent with the other findings), and failure to
adjust for relevant potential confounding variables. How-
ever, given also that two of the three studies not finding an
association were in children or adolescents where
reported prevalence was very low indeed, and that the
results are supported by an experimental study [18] show-
ing a clearly lower risk in users of portion-bag than loose
snuff, a true effect seems quite probable.
Conclusion
Detailed assessment of the overall risks and benefits of ST
use to the public health would require consideration of
the whole spectrum of its possible health effects and is
beyond the scope of this review. However, we do note that
there are numerous reports, including our own publica-
tions on oral cancer [57] and on circulatory disease [56],
which support the risks of smoking-related diseases from
ST as being generally much less than those from smoking.
This review confirms the strong relationship of oral
mucosal lesions to ST use, shows that prevalence and
severity is related to the type and amount of the product
used, and that the lesion is reversible on quitting. The evi-
dence relating other oral lesions to ST use is less clear. A
causal relationship of snuff use with gingival recession
seems probable, but not certain. The relationships
between CT use and dental caries and between ST use and
attachment loss are less clear, and the evidence here may
be regarded only as suggestive of a causal relationship.
There seems no real indication that ST use affects gingivitis
(or gingival bleeding). Data are too limited to draw relia-
ble conclusions for other endpoints, including oral pain.
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